ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

gilteritinib

Also written as “Gilteritinib”, “ASP2215” and “gilteritinib mini tablet”.

Its studies are mostly in Leukemia, Myeloid, Acute · Carcinoma, Non-Small-Cell Lung, led by 3 companies.

Drug pageGilteritinib: every studyAll 41 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 16, 201520 company-led studies, 2 open or runningNext primary completion: Jul 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharma182 open or runningphase 3since Apr 16, 2015Nov 6, 2013Jul 31, 2028phase 2 · NCT05520567
AbbVieits history only10 open or runningphase 1since Aug 8, 2018Aug 8, 2018none ahead
Bristol-Myers Squibbits history only10 open or runningphase 1since Mar 26, 2020Mar 26, 2020none ahead

Also a collaborator on its studies: Hoffmann-La Roche.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Astellas Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Nov 6, 2013.

  1. Apr 16, 2015Phase 3 study in Leukemia, Myeloid, AcuteNCT02421939 · 371 enrolled · United States, Belgium, Canada and more
  2. May 27, 2015Phase 1 study in Advanced Solid TumorsNCT02456883 · 6 enrolled · United States
  3. Sep 25, 2015Phase 2 study in Leukemia, Myeloid, AcuteNCT02561455 · 9 enrolled · United States
  4. Oct 7, 2015Phase 1 study in Hepatic ImpairmentNCT02571816 · 24 enrolled · United States
  5. Apr 22, 2016Phase 3 study in Leukemia, Myeloid, AcuteNCT02752035 · 183 enrolled · United States, Australia, Belgium and more
  6. Oct 5, 2016Phase 2 study in Leukemia, Myeloid, AcuteNCT02927262 · 98 enrolled · United States, Brazil, Canada and more
  7. Dec 1, 2016Phase 3 study in Leukemia, Myeloid, AcuteNCT02997202 · 356 enrolled · United States, Australia, Belgium and more
  8. Jun 8, 2017Phase 3 study in Leukemia, Myeloid, AcuteNCT03182244 · 276 enrolled · China, Malaysia, Russia and more
  9. Nov 1, 2018Phase 2 study in Leukemia, Myeloid, AcuteNCT03730012 · 11 enrolled · United States
  10. May 20, 2019Phase 1 study in Healthy VolunteerNCT03964038 · 48 enrolled · United States
  11. Jan 21, 2020Phase 2 study in Leukemia, Myeloid, AcuteNCT04240002 · 9 enrolled · United States, Germany, Italy and more
  12. Jan 6, 2021Phase 1 study in Renal ImpairedNCT04699877 · 17 enrolled · United States, Bulgaria
  13. Aug 26, 2022Phase 2 study in Leukemia, Myeloid, AcuteNCT05520567 · 70 enrolled · United States
  14. Aug 5, 2025Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07140016 · 40 planned · United States, France, Spain

Ahead

  1. Jul 31, 2028Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT05520567
  2. Dec 31, 2029Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07140016

TargetBeta

“An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), ”NCIt, by rule
“Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase receptor UFO inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase receptor UFO inhibitor”ChEMBL 37, by rule

Studies

All 18 Astellas Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07140016Carcinoma, Non-Small-Cell Lung · United States, France, Spain1RecruitingDec 31, 202940
NCT05520567Leukemia, Myeloid, Acute · United States2Active, not recruitingJul 31, 202870
NCT04699877Renal Impaired · United States, Bulgaria1CompletedJul 18, 202217
NCT04240002Leukemia, Myeloid, Acute · United States, Germany, Italy and more2TerminatedMar 11, 20259
NCT03964038Healthy Volunteer · United States1CompletedJul 2, 201948
NCT03730012Leukemia, Myeloid, Acute · United States2CompletedMay 14, 202111
NCT03182244Leukemia, Myeloid, Acute · China, Malaysia, Russia and more3CompletedDec 25, 2023276
NCT02997202Leukemia, Myeloid, Acute · United States, Australia, Belgium and more3CompletedJan 7, 2023356
NCT02927262Leukemia, Myeloid, Acute · United States, Brazil, Canada and more2CompletedMay 25, 202198
NCT02752035Leukemia, Myeloid, Acute · United States, Australia, Belgium and more3CompletedMar 10, 2023183
NCT02571816Hepatic Impairment · United States1CompletedMar 5, 201624
NCT02561455Leukemia, Myeloid, Acute · United States2CompletedJul 28, 20209
NCT02456883Advanced Solid Tumors · United States1CompletedMay 20, 20176
NCT02421939Leukemia, Myeloid, Acute · United States, Belgium, Canada and more3CompletedSep 17, 2018371
NCT02310321Leukemia, Myeloid, Acute · Japan, South Korea, Taiwan2CompletedAug 25, 202197
NCT02236013Leukemia, Myeloid, Acute · United States1CompletedJul 26, 202180
NCT02181660Leukemia, Myeloid, Acute · Japan1CompletedJun 27, 201624
NCT02014558Leukemia, Myeloid, Acute · United States, Germany, Italy2CompletedAug 4, 2017265

How it is read

Names in the registry

  • “Gilteritinib”, 11 entries
  • “gilteritinib”, 7 entries
  • “ASP2215”, 1 entry
  • “gilteritinib mini tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.